- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Categories
Research & Science
Power3 Medical Products, Inc. was highlighted in an article in the January issue of Woman’s Day Magazine in the “Health Your Health” section.
Lexicon Pharmaceuticals, Inc. has announced that Arthur T. Sands, M.D., Ph.D., President and CEO, will present at the JPMorgan Healthcare Conference in San Francisco, California on January 10.
Lexicon Pharmaceuticals, Inc. has submitted an investigational new drug (IND) application to the FDA for LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.
Power3 Medical Products, Inc. recently presented at the San Antonio Breast Cancer Symposium.
A member of Lexicon's senior management will participate in the RBC Capital Markets Healthcare Conference panel in New York on Wednesday, December 12.
Lexicon Pharmaceuticals, Inc. has announced that dosing has commenced in a Phase 2a clinical trial with LX6171, an oral drug candidate for the treatment of cognitive impairment.
Repros Therapeutics Inc. has announced that its lead product, Proellex®, has entered into Phase 3 studies.
Lexicon Pharmaceuticals, Inc. will present at the Piper Jaffray 19th Annual Health Care Conference.
Lexicon Pharmaceuticals, Inc. has submitted an investigational new drug (IND) application to FDA for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.
Power3 Medical Products, Inc. applauds Laura Bush’s campaign in the Middle East for breast cancer awareness.
Power3 Medical Products, Inc. has appointed Dr. Marwan N. Sabbagh to the Company’s Scientific Advisory Board.
Power3 Medical Products, Inc. has signed its first distribution agreement to provide BC-SeraPro™, its breast cancer blood serum diagnostic test.
